Call for your appointment today 914-666-4665 | Mt. Kisco, New York
Reshaping the future of medicine.
Uncovering an immune-mediated root cause for chronic CNS and cardiovascular disorders.
Our Company
Transforming care with precision medicine.
At Moleculera Biosciences, a precision medicine company, we envision a world in which patients will be treated by targeting an identified, underlying root cause, rather than simply treating symptoms. We look beneath the surface of complex disorders to discover if there is an immune-mediated basis for chronic central nervous system (CNS) and cardiovascular disorders.
Once an immune-mediated root is identified, tailored treatments can dramatically improve a patient’s life – greatly reducing or eliminating symptoms that were once debilitating.
Our Technology Platform
Harnessing the power of real-world data to improve patients’ lives.
We are intently focused on the discovery and development of next-generation technologies for the identification, diagnosis, and treatment of patients suffering from immune-mediated neuropsychiatric, cardiovascular, Long-COVID and neuro-degenerative disorders.
Our unique technology platform consists of three integrated components, which, when utilized together, lead to unprecedented discoveries. Moleculera’s platform includes: blood-based autoantibody testing panels, an expansive biorepository of phenotypically curated specimens, and a novel biomarker and targeted therapeutic identification program.
Precision Medicine
Blood Panel
Blood Panel
Heavily researched biomarker targets of immune dysfunction directed against an organ system, leading to disease
Biobank and
Bioinformatics
Bioinformatics
Curated, longitudinal, clinically annotated biobank and medical data of patient treatments and outcomes
Target Identification
Programs
Programs
Identification of new biomarkers for companion diagnostics and novel targets for therapy
Our Science
Multiple Translational Programs
Moleculera Biosciences is advancing multiple translational programs to address the unmet needs of patients suffering from chronic, immune-mediated neuropsychiatric, cardiovascular, Long-COVID, and neuro-degenerative disorders. The company has a robust pipeline of multiple autoantibody panels including: the Autoimmune Brain Panel™ (our signature program already in the market), the Autoimmune Heart Panel™, the Long-COVID Panel™, and the Neuro-degenerative Disorder Panel™.
Autoimmune
Brain Panel™
Autoimmune
Cardiovascular Panel™
Long-COVID
Panel™
Neuro-degenerative
Disorder Panel™
Autoimmune Brain Panel™
Improving patient care through precision testing.
The Autoimmune Brain Panel™ includes a series of five high-complexity blood tests that assists clinicians in determining whether a patient’s neuropsychiatric symptoms may be due to a treatable autoimmune dysfunction, rather than a primary neurologic or psychiatric illness. Once diagnosed and treated properly, patients often experience a complete resolution or dramatic reduction in symptoms.
Only test of its kind
Providing hope for patients with treatment-resistant neuropsychiatric conditions.
Approximately 800 million individuals worldwide 1 suffer from neurologic, psychiatric and behavioral disorders. Typically, patients are treated with psychotropic or anti-seizure medications. However, 20-60% of these patients do not respond to treatment 2. Research indicates that in some of these cases, patients do not improve because the root cause is immune-mediated and goes undiagnosed.
That’s all changing with the Autoimmune Brain Panel™ – the only commercially available test of its kind that assists clinicians in diagnosing and treating immune-mediated neuropsychiatric disorders.
Neuropsychiatric symptoms that may be caused by an autoimmune reaction
Anxiety Disorders
In some people, symptoms associated with anxiety disorders may be caused by an infection-triggered autoimmune encephalopathy.
Obsessions & Compulsions
Increasing evidence suggests that an abnormal immune response, often triggered by an infection, can cause obsessive compulsive behaviors.
Motor & Vocal Tics
Among adults with new onset tics, 1 in 3 are likely to have an external precipitating event, such as an infection, trigger the disorder.
Depression & Mood Changes
Certain infection(s) can trigger an autoimmune attack on the brain, resulting in inflammation and the onset of neuropsychiatric symptoms, including major depression, bipolar disorder and sudden mood changes.
Attention Deficit & Hyperactivity
While the cause of ADHD is still unknown, researchers believe genetics, diet, environmental factors, and infections play a role.
Chronic Fatigue Syndrome
Chronic fatigue syndrome is often reported to be triggered by infections and the link between infections and autoimmune diseases is well established.
Autism Spectrum Disorder
The evidence that immune dysfunction likely plays a role in the etiology/pathophysiology of ASD (autism spectrum disorder) is becoming substantial.
Lyme Disease
In some individuals, an infection with Borrelia burgdorferi (the causative agent of Lyme disease) can ignite an autoimmune response, resulting in neurologic and psychiatric symptoms.
Epilepsy / Seizure Disorders
Mounting evidence also indicates that an immune dysfunction or abnormal autoimmune activity can elicit a sudden onset of seizures in adults with no history of the illness.
PANS & PANDAS
PANS and PANDAS are infection-triggered autoimmune disorders affecting the basal ganglia, which can result in a multitude of neuropsychiatric symptoms.
Empowering Science.
0
+
clinicians utilizing the platform
0
+
patients tested
0
+
years of research and development
Want to learn more?
We’re here to help you better understand the Autoimmune Brain Panel™ and how it can benefit you or your patients.
Medical Resources For Healthcare Providers
We are committed to helping healthcare providers improve clinical outcomes for patients with treatment resistant neuropsychiatric symptoms.
Could your symptoms be due to an immune dysfunction?
Answer a few questions to find out if you might benefit from testing with the Autoimmune Brain Panel™.
IN THE NEWS
Moleculera Forms Strategic Collaboration with Quest Diagnostics
Companies Collaborate to Broaden Access to Moleculera’s Novel Neuropsychiatric Autoantibody Testing
Moleculera Awarded $500,000 Grant Funding to Develop Predictive Treatment Algorithm
Company leveraging strategic alliance with General Genomics to build next-gen predictive treatment model for immune-mediated neuropsychiatric disorders
Moleculera and General Genomics Form Strategic Alliance
To Utilize Proprietary AI to Provide Personalized Medicine for Autoimmune Neuropsychiatric Disorders